In Memory of Steve Jobs Will Novartis Sales Reps Really Embrace iPads?
David Epstein, head of Novartis Pharmaceuticals, said eighty percent of his company's sales reps will give up their PCs for iPads in 2012. Will they do it?
Pharma Marketing News Vol. 10, No. 11: 21 June 2011
Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.
Pharma TeleWeb e-Detailing
This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.
Politics Vs. Science in the Plan B Decision
Sebelius focused on the fact that Teva's study did not contain data for all ages for which this product would be available for use. According to Tina Raine-Bennett, MD, MPH, of the Women's Health Research Institute at Kaiser Permanente Northern California, a principal investigator of the University of California-San Francisco study, it is unreasonable and virtually impossible to study the use of emergency contraception in 11- and 12-year-olds, because only a small fraction of them will have had sex by that age.
Fair Social Media Practice Principles
Rules for Third-Party Engagement in Patient/Physician Social Networks. A Social Media Policy is not just an agreement that users must abide by. More importantly, it is a PROMISE to users from site owners/sponsors concerning how they will protect or attempt to protect user-generated content, personal conversations, interactions, and engagements with third-parties on the site. These policies should comply with as-yet-to-be-determined, universally accepted 'fair social media practice principles.'
Pharma Marketing News Vol. 10, No. 6: 29 MARCH 2011
Welcome to Volume 10, Issue #6 (30 MARCH 2011) of Pharma Marketing News.
The Socialisation of the Internet is Bogus
The whole web is now socialised..
Digitally-Feeble Pharma
Is Your Brand a Digital Genius or a Feeble-Minded Idiot? When it comes to digital IQ, some brands are geniuses and some are feeble-minded idiots, according to the 'L2 Digital IQ Index' for pharmaceutical brands, a first-of-its kind measurement of the digital competence of 51 pharma brands across eight therapeutic categories.
Adverse Event Reporting: A Missed Opportunity
When asked what the # 1 concern pharmaceutical marketers have regarding using social media, the adverse event reporting (AER) boogey man is cited most often. The urge to avoid this boogey man at all costs may have more to do with CEO compensation that with fears of rank-an-file marketers.
PR & Interactive Agencies Vie for Pharma Social Media Campaign Crumbs
Should a PR firm or an interactive marketing agency be in charge of pharma social media campaigns?
